Table 2.
Dosages and treatment durations in different lines of therapy.
| Line of Treatment | Drug | N. of Patients | Median Dose, mg/day (Range) | Median Duration of Treatment, Months (Range) |
|---|---|---|---|---|
| First line (n = 123) | ||||
| IMA | 106 (86.1) | 400 (100–800) | 41.9 (1–201) | |
| NIL | 7 (5.6) | 600 (300–600) | 48.2 (7–102) | |
| DAS | 9 (7.1) | 100 (50–100) | 46.7 (3–102) | |
| BOS | 1 (0.8) | 400 | 31 | |
| Second line (n = 31) | ||||
| IMA | 1 (3.2) | 400 | 77 | |
| NIL | 6 (19.3) | 600 (400–800) | 58.6 (5–116) | |
| DAS | 13 (41.9) | 100 (50–300) | 46.1 (7–105) | |
| BOS | 9 (29.0) | 300 (100–500) | 18.4 (3–87) | |
| PON | 2 (6.4) | 15–30 | 39 (8–70) | |
| Third line (n = 9) | ||||
| NIL | 2 (22.2) | 200–400 | 48 (46–50) | |
| DAS | 1 (11.1) | 50 | 119 | |
| BOS | 1 (11.1) | 300 | 21 | |
| PON | 5 (55.5) | 15 (15–45) | 32.2 (1–91) | |
| Fourth line (n = 1) | ||||
| ASC | 1 | 400 | 45 | |
ASC, asciminib; BOS, bosutinib, DAS, dasatinib; IMA, imatinib; NIL, nilotinib; PON, ponatinib.